PACMx5 — Competitive Intelligence Brief

PACMx5 (PACMx5) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Personalized neoantigen vaccine. Area: Oncology.

phase 3 Personalized neoantigen vaccine Oncology Small molecule

Target snapshot

PACMx5 (PACMx5) — SWOG Cancer Research Network. PACMx5 is a personalized neoantigen vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PACMx5 TARGET	PACMx5	SWOG Cancer Research Network	phase 3	Personalized neoantigen vaccine
aMIL	aMIL	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
SK-PC-B70M	SK-PC-B70M	SK Chemicals Co., Ltd.	phase 3	Cancer vaccine (personalized neoantigen vaccine)
IMA901	IMA901	Immatics Biotechnologies GmbH	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
mRNA-1010	mRNA-1010	ModernaTX, Inc.	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
IO102-IO103	IO102-IO103	IO Biotech	phase 3	Personalized neoantigen vaccine + checkpoint inhibitor combination	Patient-specific neoantigens; CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Personalized neoantigen vaccine class)

1. Immatics Biotechnologies GmbH · 2 drugs in this class
2. ModernaTX, Inc. · 1 drug in this class
3. SWOG Cancer Research Network · 1 drug in this class
4. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in this class